JBIO Projected Dividend Yield
Jade Biosciences Inc. ( NASDAQ : JBIO )Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the U.S. and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. 21 YEAR PERFORMANCE RESULTS |
JBIO Dividend History Detail JBIO Dividend News JBIO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |